文献速递乳腺癌放疗放疗物理与技术

早期乳腺癌术前机器人放射外科治疗:II期ROCK试验(NCT03520894)结果

Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894).
PubMed 文献 · Clin Transl Radiat Oncol · 2022-09-22

II期ROCK试验在2018至2021年招募50岁以上、激素受体阳性/HER2阴性、肿瘤≤25 mm的早期乳腺癌患者,评估术前机器人放射外科单次21 Gy的急性和早期晚期毒性、疾病控制与美容效果。22例患者成功接受治疗,未观察到超过G2的急性或早期晚期毒性,中位随访18个月时多数美容效果为优秀/良好。

要点

  • 术前机器人放射外科单次21 Gy在选择的早期乳腺癌患者中可行,初步毒性可接受。
  • 急性毒性仅见G1不良事件和1例G2乳腺水肿,无超过G2的急性毒性。
  • 早期晚期毒性为5例G1和1例G2乳腺硬结,无超过G2的早期晚期毒性。

核心结论

  • ROCK试验表明,单次21 Gy术前机器人放射外科是选择早期乳腺癌患者的一种可行技术,初步毒性可接受。

研究设计与样本

  • II期ROCK试验(NCT03520894)于2018至2021年在本中心放射肿瘤科招募患者。
  • 纳入标准为50岁以上、激素受体阳性/人表皮生长因子受体2阴性(HR+/HER2-)、肿瘤大小不超过25 mm的乳腺癌患者。
  • 研究前瞻性评估术前机器人单次21 Gy放射外科的毒性和可行性;共招募70例患者,22例成功接受治疗。

主要发现

  • 术后7天内记录到3例G1不良事件(13.6%)。
  • 术后7至30天记录到3例事件(13.6%),包括1例G2乳腺水肿和2例G1乳腺疼痛;未记录到超过G2的急性毒性。
  • 5例患者出现早期晚期G1毒性,1例报告G2乳腺硬结;未观察到超过G2的早期晚期毒性。
  • 中位随访18个月(范围6-29.8个月)时,美容效果评为优秀/良好者14例、一般者5例、差者3例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Preoperative partial breast irradiation (PBI) has got the advantage of treating a well-defined target. We report the results of the phase II ROCK trial (NCT03520894), enrolling early breast cancer (BC) patients treated with preoperative robotic radiosurgery (prRS), in terms of acute and early late toxicity, disease control, and cosmesis. MATERIAL AND METHODS: The study recruited between 2018 and 2021 at our Radiation Oncology Unit. Eligible patients were 50 + years old BC, hormonal receptors positive/human epidermal growth factor receptor 2 negative (HR+/HER2-), sized up to 25 mm. The study aimed to prospectively assess the toxicity and feasibility of a robotic single 21 Gy-fraction prRS in preoperative setting. RESULTS: A total of 70 patients were recruited and 22 patients were successfully treated with pRS. Overall, three G1 adverse events (13.6 %) were recorded within 7 days from prRS. Three events (13.6 %) were recorded between 7 and 30 days, one G2 breast oedema and two G1 breast pain. No acute toxicity greater than G2 was recorded. Five patients experienced early late G1 toxicity. One patient reported G2 breast induration. No early late toxicity greater than G2 was observed. At a median follow up of 18 months (range 6-29.8), cosmetic results were scored excellent/good and fair in 14 and 5 patients, respectively, while 3 patients experienced a poor cosmetic outcome. CONCLUSIONS: ROCK trial showed that a single 21 Gy dose prRS represents a feasible technique for selected patients affected by early BC, showing an acceptable preliminary toxicity profile.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Meattini I, Francolini G, Di Cataldo V, et al. Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894). Clin Transl Radiat Oncol. 2022. PMID: 36177053. doi:10.1016/j.ctro.2022.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。